Rapid ASPECTS receives clearance as first neuroimaging analysis device in computer-aided diagnostic category.
Advanced stroke imaging company RapidAI announced today it has secured 510(k) clearance from the U.S. Food & Drug Administration for its neuroimaging analysis device Rapid ASPECTS.
This is the first device to receive clearance in the computer-aided diagnostic software (CADx) category, and, according to a company statement, it is the only product confirmed to improve physician interpretations of non-contract CT using a standardized APSECT score. It can be particularly useful for less experienced readers, company officials said.
“The FDA’s advanced CADx clearance has never been granted to a neuroimaging solution before,” said Jim Rosa, senior vice president of regulatory and clinical at RapidAI. “Through a combination of clinically validated advances in AI and machine learning, Rapid ASPECTS offers a glimpse into the future of stroke imaging.”
Related Content: CT Predicts Stroke Patients Benefitting From Endovascular Thrombectomy
Rapid ASPECTS is based on the Alberta Stroke Program Early CT Scoring (ASPECTS) system, and it uses a validated machine-learning algorithm to identify affected regions of the brain and create an ASPECT score than can pinpoint early signs of stroke in non-contrast CT scans. In doing so, it can help providers identify areas of the brain that have irreversible injury.
Overall, according to company information, Rapid ASPECTS offers three main features:
Ultimately, company officials said, Rapid ASPECTS is designed to facilitate better patient outcomes.
“Rapid ASPECTS represents the next AI-powered step forward in stroke imaging, and the groundbreaking CADx clearance from the FDA puts it in a class by itself,” said RapidAI co-founder Greg Albers, M.D., professor of neurology at Stanford University and director of the Stanford Stroke Center. “In addition to helping stroke teams with faster triage and transfer decision, Rapid ASPECTS also improves the accuracy of typical readers.”
Rapid ASPECTS is already available internationally and will be commercially available in the United States later in July.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 3
August 5th 2025In the last of a three-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, share additional insights on practical considerations and potential challenges in integrating abbreviated breast MRI into clinical practice, and offer their thoughts on future research directions.
Reducing the Interval Breast Cancer Rate of Screening DBT: Can AI Have an Impact?
August 5th 2025In a retrospective review of screening digital breast tomosynthesis (DBT) exams for over 200 women with interval breast cancers, researchers found that AI provided accurate localization of cancers in 32.6 percent of the cases.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 5th 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
Chest CT for Post-COVID-19 Abnormalities: Nine Takeaways from a Multi-Society Consensus Statement
August 5th 2025Developed by 21 thoracic radiologists, the new international consensus statement addresses appropriate indications, scan acquisition and keys to reporting for the use of chest CT imaging in evaluating for residual lung abnormalities from COVID-19.